Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Tyme Technologies stock price, quote, forecast and news

TYME
US90238J1034
A14XMS

Price

0.31
Today +/-
+0
Today %
+0 %
P

Tyme Technologies stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Tyme Technologies stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Tyme Technologies stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Tyme Technologies stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Tyme Technologies's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Tyme Technologies Stock Price History

DateTyme Technologies Price
9/16/20220.31 undefined
9/15/20220.29 undefined

Tyme Technologies Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Tyme Technologies, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Tyme Technologies from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Tyme Technologies’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Tyme Technologies. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Tyme Technologies’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Tyme Technologies’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Tyme Technologies’s growth potential.

Tyme Technologies Revenue, EBIT and net profit per share

DateTyme Technologies RevenueTyme Technologies EBITTyme Technologies Net Income
2025e-9,351.7 TT undefined0 undefined-172.21 M undefined
2024e-9,160.81 TT undefined0 undefined0 undefined
2023e1.31 M undefined0 undefined0 undefined
20220 undefined-23.08 M undefined-23.63 M undefined
20210 undefined-27.22 M undefined-28.98 M undefined
20200 undefined-25.76 M undefined-22 M undefined
20190 undefined-29.31 M undefined-32.98 M undefined
20180 undefined-19.36 M undefined-18.97 M undefined
20170 undefined-15.21 M undefined-15.21 M undefined
20150 undefined-8.6 M undefined-11.73 M undefined
20140 undefined-50,000 undefined-50,000 undefined
20130 undefined-60,000 undefined-60,000 undefined
20120 undefined-30,000 undefined-30,000 undefined
20110 undefined0 undefined0 undefined

Tyme Technologies Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (k)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201120122013201420152017201820192020202120222023e2024e2025e
000000000001,000-9.16 TT-9.35 TT
-------------916,080,900,000,100.002.08
--------------
00000000000000
0000-8-15-19-29-25-27-23000
--------------
0000-11-15-18-32-22-28-2300-172
-----36.3620.0077.78-31.2527.27-17.86---
3947.6525277.8584.4590.57102.35114.53134.25172.21000
--------------
Details

Keystats

ⓘ

Revenue and Growth

The Tyme Technologies Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Tyme Technologies is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (k)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20112012201320142015201720182019202020212022
                     
0.010.02004.4510.4828.9814.326.7107.5274.35
00000000000
00000000000
00000000000
00000.030.230.731.841.382.144.55
0.010.02004.4810.7129.7116.1428.08109.6678.9
0000101001016075.4738.23
00000000009.08
00000000000
00000000000
00000000000
0000001.311.371.270.530
00000.010.011.311.381.430.619.12
0.010.02004.4910.7231.0217.5229.51110.2688.02
                     
00010101010101017.2217.22
0.010.040.040.0418.9141.4279.2995.47126.83238.57241.03
0-0.03-0.09-0.14-15.9-33.86-52.83-85.81-107.82-136.79-160.42
00000-0.180000-0.54
00000000000
0.010.01-0.05-0.093.027.3926.479.6719.02101.880.08
000.010.011.412.882.623.332.673.63.47
0000001.251.51.861.080.97
000.030.090.070.450.190.790.540.972.94
00000048060052000
00000000000
000.040.11.483.334.546.225.595.647.39
00000000000
00000000000
00000001.644.892.820.55
00000001.644.892.820.55
000.040.11.483.334.547.8610.488.477.93
0.010.01-0.010.014.510.7231.0117.5329.5110.2688.02
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Tyme Technologies provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Tyme Technologies's financial health and stability.

Assets

Tyme Technologies's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Tyme Technologies must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Tyme Technologies after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Tyme Technologies's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20112012201320142015201720182019202020212022
0000-11-15-18-32-22-28-23
00000000000
00000000000
00000102000
000048710252
00000000000
00000000000
0000-6-5-11-20-19-23-21
00000000000
0000000000-72
0000000000-72
00000000000
00000000000
0000710305321040
00001110305311040
00002000000
00000000000
00004418-141280-93
0-0.03-0.05-0.06-6.61-5.86-11.88-20.14-19.56-23.56-21.24
00000000000

Tyme Technologies stock margins

The Tyme Technologies margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Tyme Technologies. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Tyme Technologies.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Tyme Technologies's sales revenue. A higher gross margin percentage indicates that the Tyme Technologies retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Tyme Technologies's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Tyme Technologies's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Tyme Technologies's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Tyme Technologies. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Tyme Technologies's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Tyme Technologies Margin History

Tyme Technologies Gross marginTyme Technologies Profit marginTyme Technologies EBIT marginTyme Technologies Profit margin
2025e0 %0 %0 %
2024e0 %0 %0 %
2023e0 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %
20110 %0 %0 %

Tyme Technologies Stock Sales Revenue, EBIT, Earnings per Share

The Tyme Technologies earnings per share therefore indicates how much revenue Tyme Technologies has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Tyme Technologies earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Tyme Technologies's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Tyme Technologies’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Tyme Technologies's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Tyme Technologies Revenue, EBIT and net profit per share

DateTyme Technologies Sales per ShareTyme Technologies EBIT per shareTyme Technologies Earnings per Share
2025e-54.3 B undefined0 undefined-1 undefined
2024e-53.2 B undefined0 undefined0 undefined
2023e0.01 undefined0 undefined0 undefined
20220 undefined-0.13 undefined-0.14 undefined
20210 undefined-0.2 undefined-0.22 undefined
20200 undefined-0.22 undefined-0.19 undefined
20190 undefined-0.29 undefined-0.32 undefined
20180 undefined-0.21 undefined-0.21 undefined
20170 undefined-0.18 undefined-0.18 undefined
20150 undefined-0.11 undefined-0.15 undefined
20140 undefined-0 undefined-0 undefined
20130 undefined-0 undefined-0 undefined
20120 undefined-0 undefined-0 undefined
20110 undefined0 undefined0 undefined

Tyme Technologies business model

Tyme Technologies Inc is a biopharmaceutical company specializing in the development of cancer drugs. The company was founded in 2011 by Steve Hoffman in New York City. Tyme Technologies Inc aims to provide a solution for the urgent need for new cancer drugs. The business model of Tyme Technologies Inc focuses on research and development of therapies for various types of cancer. The company takes an innovative approach by targeting the metabolism of tumor cells to combat them. The goal is to provide personalized medicine to cancer patients, tailored to their specific cancer types and with fewer side effects. Tyme Technologies has achieved success in various areas and is actively working on establishing cancer treatment products. The company engages in its own research as well as collaborations with other companies and institutions. One of Tyme Technologies' areas of focus is the research and development of drugs for triple-negative breast cancer. This type of cancer is known to be very aggressive and spreads quickly. Tyme Technologies has developed a promising drug called SM-88, which aims to disrupt the metabolic processes in cancer cells, causing them to die. Another significant project of Tyme Technologies is the research and development of drugs for glioma, a particularly aggressive brain tumor for which there are currently no effective therapies. The company has successfully tested the drug SM-88 in a phase II study for this purpose. Tyme Technologies has also focused on cancer treatment in children. The company has conducted clinical trials for the treatment of neuroblastoma and osteosarcoma, both of which are rare and particularly aggressive types of cancer that mainly affect children. In terms of product offerings, Tyme Technologies has introduced various products to the market. One of them is the NLC-001 immunotherapy program, which focuses on activating the body's immune response against cancer cells. The company has also developed a test procedure for personalizing therapy in patients with triple-negative breast cancer, based on the patient's genetic profile. In summary, Tyme Technologies Inc is an emerging biopharmaceutical company specializing in the development of personalized therapies to combat various types of cancer. With its innovative technology, the company has already achieved significant success, particularly in the development of drugs for triple-negative breast cancer and brain tumors. The company continuously collaborates with other companies and institutions and invests in research and development of new cancer drugs in the long term. Tyme Technologies is one of the most popular companies on Eulerpool.com.

Tyme Technologies SWOT Analysis

Strengths

Tyme Technologies Inc has several strengths that contribute to its success in the market. Firstly, the company has a strong portfolio of innovative products, positioning it as a leader in the pharmaceutical industry. Secondly, Tyme Technologies has a highly skilled and experienced team, allowing for efficient development and commercialization of its products. Thirdly, the company has established strategic partnerships with key industry players, enabling access to resources, expertise, and distribution channels.

Weaknesses

Despite its strengths, Tyme Technologies Inc also faces certain weaknesses that need to be addressed to maintain its competitive edge. One weakness is the company's heavy reliance on a limited number of product lines, which exposes it to market fluctuations and potential revenue risks. Additionally, Tyme Technologies may lack sufficient financial resources to fully exploit the market opportunities and invest in research and development.

Opportunities

Tyme Technologies Inc operates in a dynamic industry with various opportunities for growth and expansion. One major opportunity lies in the increasing demand for innovative healthcare solutions and personalized medicine. Furthermore, the company can leverage advancements in technology to develop new product offerings and enhance its existing portfolio. Additionally, expanding into new geographical markets or partnering with international organizations can create new avenues for revenue generation.

Threats

Despite its strengths and opportunities, Tyme Technologies Inc also faces threats that can impact its success. One significant threat is intense competition from both established pharmaceutical companies and emerging biotech firms. Additionally, stringent regulations and compliance requirements within the industry can pose challenges and limit the company's market access. Economic uncertainties and fluctuations in healthcare policies may also impact Tyme Technologies' profitability and business operations.

Tyme Technologies Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Tyme Technologies historical P/E ratio, EBIT, and P/S ratio.

Tyme Technologies shares outstanding

The number of shares was Tyme Technologies in 2023 — This indicates how many shares 172.207 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Tyme Technologies earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Tyme Technologies's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Tyme Technologies’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Tyme Technologies's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Tyme Technologies Stock splits

In Tyme Technologies's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Tyme Technologies.

Tyme Technologies list of shareholders

%
Name
Stocks
Change
Date
5.80696 % Eagle Pharmaceuticals Inc10,000,00007/1/2022
2.30404 % The Vanguard Group, Inc.3,967,72094,3656/30/2022
13.03597 % Demurjian (Michael)22,448,846-160,0009/7/2022
1.16139 % Healthcare Value Capital, LLC2,000,000500,0009/30/2021
1.08851 % BlackRock Institutional Trust Company, N.A.1,874,488-132,7406/30/2022
0.71235 % Renaissance Technologies LLC1,226,721-34,0906/30/2022
0.46494 % Geode Capital Management, L.L.C.800,66736,8366/30/2022
0.29041 % Pathstone500,10906/30/2022
0.19860 % Hightower Advisors, LLC342,00006/30/2022
0.17140 % State Street Global Advisors (US)295,17012,9006/30/2022
1
2
3
4
5
...
10

Tyme Technologies Executives and Management Board

Mr. Richard Cunningham51
Tyme Technologies Chief Executive Officer, Director (since 2020)
Compensation 1.34 M
Mr. Frank Porfido58
Tyme Technologies Chief Financial Officer
Compensation 1.22 M
Mr. James Biehl58
Tyme Technologies Chief Legal Officer, Corporate Secretary (since 2017)
Compensation 1.19 M
Dr. Jonathan Eckard48
Tyme Technologies Chief Business Officer
Compensation 858,789
Mr. Douglas Michels65
Tyme Technologies Chairman of the Board (since 2018)
Compensation 166,335
1
2

Tyme Technologies Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Eagle Pharmaceuticals Stock
Eagle Pharmaceuticals
SupplierCustomer0,51-0,160,430,430,18-0,22
Applied DNA Sciences Stock
Applied DNA Sciences
SupplierCustomer0,230,820,640,930,950,83
1

Most common questions regarding Tyme Technologies

What values and corporate philosophy does Tyme Technologies represent?

Tyme Technologies Inc represents a commitment to innovation, patient-centricity, and scientific rigor. With a focus on advancing breakthrough cancer treatments, the company's corporate philosophy emphasizes the importance of delivering safe and effective therapies that improve patients' lives. Tyme Technologies Inc is dedicated to conducting rigorous research and clinical studies that advance the understanding and treatment of various forms of cancer. Their mission is to revolutionize cancer care by developing novel therapies that target the metabolic and genetic pathways unique to cancer cells. Through their cutting-edge approach, Tyme Technologies Inc strives to bring hope and new treatment options to cancer patients worldwide.

In which countries and regions is Tyme Technologies primarily present?

Tyme Technologies Inc is primarily present in the United States.

What significant milestones has the company Tyme Technologies achieved?

Tyme Technologies Inc has achieved several significant milestones. One of the major milestones for the company was obtaining orphan drug designation from the U.S. FDA for its lead product candidate, SM-88. Tyme also successfully completed a Phase II trial for SM-88 in patients with metastatic pancreatic cancer. Furthermore, the company has expanded its clinical pipeline by initiating Phase II trials for SM-88 in additional types of cancer, including prostate and breast cancer. Tyme Technologies Inc has demonstrated promising progress in advancing its innovative therapies and is poised for further growth and development.

What is the history and background of the company Tyme Technologies?

Tyme Technologies Inc is a pharmaceutical company focused on developing innovative cancer treatments. Founded in 2011, the company is headquartered in New York, USA. Tyme Technologies is committed to improving the lives of cancer patients through its proprietary research and development activities. The company focuses on the development of cancer metabolism-based therapies that have the potential to overcome drug resistance, reduce side effects, and provide more effective treatment options. Tyme Technologies is dedicated to advancing its pipeline of novel therapies, with a particular focus on metastatic cancers.

Who are the main competitors of Tyme Technologies in the market?

The main competitors of Tyme Technologies Inc in the market are pharmaceutical companies that focus on developing and marketing cancer treatments. These competitors include well-established companies such as Roche Holdings AG, Pfizer Inc, and Merck & Co. Tyme Technologies Inc faces competition in the development and commercialization of its lead candidate, SM-88, which aims to treat multiple types of cancers. Nonetheless, Tyme Technologies Inc differentiates itself through its innovative approach and unique molecular platform.

In which industries is Tyme Technologies primarily active?

Tyme Technologies Inc is primarily active in the pharmaceutical industry.

What is the business model of Tyme Technologies?

Tyme Technologies Inc. is a biotechnology company based in New York, USA. The business model of Tyme Technologies Inc. primarily focuses on the development and commercialization of innovative cancer therapies. The company concentrates on creating therapies that target cancer metabolism and harness the body's immune system response. Through extensive research and clinical trials, Tyme Technologies Inc. aims to provide patients with effective and personalized treatment options for various types of cancer. Their commitment to advancing cancer care and improving patient outcomes drives their business model. Tyme Technologies Inc. strives to revolutionize cancer treatment through their innovative therapies and dedication to scientific advancements.

What is the P/E ratio of Tyme Technologies 2024?

The Tyme Technologies P/E ratio is 0.

What is the P/S ratio of Tyme Technologies 2024?

The Tyme Technologies P/S ratio is -0.

What is the AlleAktien quality score of Tyme Technologies?

The AlleAktien quality score for Tyme Technologies is 2/10.

What is the revenue of Tyme Technologies 2024?

The expected Tyme Technologies revenue is -9,160.81 TT USD.

How high is the profit of Tyme Technologies 2024?

The profit cannot currently be calculated for Tyme Technologies.

What is the business model of Tyme Technologies

Tyme Technologies Inc. is a research-based biotechnology company that develops innovative cancer therapies. The company is headquartered in New York, USA and was founded in 2011. Tyme focuses on manufacturing drugs that aim to improve the current standard of cancer treatment. Tyme Technologies' business model is focused on the development, manufacturing, and marketing of new cancer drugs. The company operates active research and development programs to discover new cancer drugs for a variety of cancer types. It also has a range of already approved products. The company is divided into various divisions that are responsible for its business activities, including research and development, manufacturing, marketing, sales, and finance. Research and Development: Tyme Technologies heavily invests in research and development to develop new cancer drugs that provide patients with a better quality of life and survival chances. The company utilizes state-of-the-art scientific methods and technologies to understand the mechanisms of cancer cells and develop new therapies. Approved Products: Tyme Technologies has already brought a drug called "SM-88" to the market. It is an oral treatment for advanced, non-resectable, or metastatic solid tumors. SM-88 has the potential to be an effective addition to current cancer treatment. Manufacturing: Tyme Technologies has a modern production facility that enables the manufacturing of drugs based on Good Manufacturing Practices (GMP). The company emphasizes high quality standards and careful quality control to ensure that its drugs are safe and effective. Marketing and Sales: Tyme Technologies develops effective marketing and sales strategies to successfully position its products in the market. The company works closely with doctors and oncologists to ensure that its products meet the needs of patients and provide the best possible therapy. Finance: Tyme Technologies is committed to supporting its business activities through an effective financing structure. The company utilizes various financing options such as public offerings, venture capital, and strategic partnerships to finance its growth and expansion. In summary, Tyme Technologies is an innovative biotech company focused on the development of cancer drugs. The company heavily invests in research and development to discover new drugs for cancer treatment. Tyme Technologies is involved in manufacturing, marketing, and sales of drugs at various levels. It has also successfully brought an approved product to the market and continues to strive for sustainable growth.

What is the Tyme Technologies dividend?

Tyme Technologies pays a dividend of 0 USD distributed over payouts per year.

How often does Tyme Technologies pay dividends?

The dividend cannot currently be calculated for Tyme Technologies or the company does not pay out a dividend.

What is the Tyme Technologies ISIN?

The ISIN of Tyme Technologies is US90238J1034.

What is the Tyme Technologies WKN?

The WKN of Tyme Technologies is A14XMS.

What is the Tyme Technologies ticker?

The ticker of Tyme Technologies is TYME.

How much dividend does Tyme Technologies pay?

Over the past 12 months, Tyme Technologies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Tyme Technologies is expected to pay a dividend of 0 USD.

What is the dividend yield of Tyme Technologies?

The current dividend yield of Tyme Technologies is .

When does Tyme Technologies pay dividends?

Tyme Technologies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Tyme Technologies?

Tyme Technologies paid dividends every year for the past 0 years.

What is the dividend of Tyme Technologies?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Tyme Technologies located?

Tyme Technologies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Tyme Technologies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Tyme Technologies from 9/16/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/16/2024.

When did Tyme Technologies pay the last dividend?

The last dividend was paid out on 9/16/2024.

What was the dividend of Tyme Technologies in the year 2023?

In the year 2023, Tyme Technologies distributed 0 USD as dividends.

In which currency does Tyme Technologies pay out the dividend?

The dividends of Tyme Technologies are distributed in USD.

All fundamentals about Tyme Technologies

Our stock analysis for Tyme Technologies Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Tyme Technologies Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.